The place of Somatostatin Analogs in the Diagnosis and Treatment of the Neuoroendocrine Glands Tumors

Recent Patents on Anti-Cancer Drug Discovery

Volumn 1, Issue 2, 2006, Pages 237-254

  Melen Mucha, Gabriela ^a   Lawnicka, Hanna ^a   Kierszniewska Stepien, Dorota ^a   Komorowski, Jan ^a   Stepien, Henryk ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Diagnosis; Neuroendocrine tumors; Somatostatin; Somatostatin analogs; Somatostatin receptor scintigraphy; Somatostatin receptor targeted therapy; Treatment

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DIAGNOSTIC AGENT; DRUG DERIVATIVE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

ANIMAL; DRUG EFFECT; HUMAN; METABOLISM; NEUROENDOCRINE TUMOR; PATENT; POSITRON EMISSION TOMOGRAPHY; REVIEW; SCINTISCANNING;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; NEUROENDOCRINE TUMORS; PATENTS AS TOPIC; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 39049103008     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489206777442197     Document Type: Article

References (190)

1. Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77-79.
2. Pradayrol L, Jornvall H, Mutt V, Ribet A. N-terminally extended somatostatin: the primary structure of Somatostatin-28. FEBS Lett 1980; 109: 55-58.
3. Shen L-P, Rutter WL. Sequence of the human somatostatin I gene. Science 1984; 224: 168-171.
4. Arimura A, Sato H, Dupont A, Nishi N, Schally A. Somatostatin: abundance of immunoreacitve hormone in the rat stomach and pancreas. Science 1975; 189: 10007-9.
5. Finley JCW, Maderdrut JL, Roger LJ, Petrusz P. The immunocytochemical localization of somatostatin-containing neurons in the rat central nervous system. Neuroscience 1981; 6: 2173-2192.
6. Patel YC, Reichlin S. Somatostatin in hypothalamus, extrahypothalamic brain and peripheral tissues of the rat. Endocrinology 1978; 102: 523-530.
7. Hokfelt T, Elfvin LG, Elde E, Schultzberg M, Goldstein M, Luft R. Occurrence of somatostatin-like immunoreactivity in some peripheral sympathetic noradrenergic neurons. Proc Natl Acad Sci USA 1977; 74: 3587-3591.
8. Reichlin S. Somatostatin. N Engl J Med 1983; 309: 1495-1501; 1556-1563.
9. Patel YC. Somatostatin. In: Becker K Ed, Principles and practice of endocrinology and metabolism. Philadelphia, Lippincott 1980; 1297-1301.
10. Aguila MC, Dees WL, Haensly, WE, McCann SM. Evidence that somatostatin is localized and synthesized in lymphoid organs. Proc Natl Acad Sci USA 1991; 88: 11485-9.
11. Elliott DE, Blum AM, Li J, et al. Preprosomatostatin messenger RNA is expressed by inflamatory cells and induced by inflamatory mediators and cytokines. J Immunol 1998; 160: 3997-4003.
12. Patel YC, Wheatley T, Ning C. Multiple forms of immunoreactive somatostatin: comparison of distribution in neural and non-neural tissues and portal plasma of the rat. Endocrinology 1981; 109: 1943-49.
13. Patel YC, Srikant CB. Somatostatin mediation of adenohypophysial secretion. Annu Rev Physil 1985; 48:551-567.
14. Gerich JE. Somatostatin. In: Brownlee M Ed, Handbook of diabetes mellitus, Vol.1. New York, Gerland STPM Press 1981; 297-354.
15. Moreau JP, DeFeudis FV. Pharmacological studies of somatostatin and somatostatin-analogues: therapeutic advances and prospectives. Life Sci 1987; 40: 419-437.
16. Yamada T. Gut somatostatin. In: Reichlin S Ed, Somatostatin. Basic and Clinical Status. New York, Plenum Press; 1987: 221-228.
17. Pawlikowski M, Kunert-Radek J, Sţepién H. Somatostatin inhibits the mitogenic effect of thyroliberin. Experientia 1978; 34: 271-271.
18. Zerek-Melen G, Lewinski A, Pawlikowski M, Sewerynek E, Kunert-Radek J. Influence of somatostatin and epidermal growth factor (EGF) on the proliferation of follicular cells in the organcultured rat thyroid. Res Exp Med 1987; 187(6): 415-21.
19. Mascardo RN, Sherline P. Somatostatin inhibits rapid centrosomal separation and cell proliferation induced by epidermal growth factor. Endocrinology 1982; 111(4): 1394-6.
20. Sharma K, Patel YC, Srikant CB. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 1996; 10(12): 1688-96.
21. Woltering EA. Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspectives. Cancer Biother Radiopharm 2003; 18(4): 601-9.
22. Stepien HM, Kolomecki K, Pasieka Z, Komorowski J, Stepien T, Kuzdak K. Angiogenesis of endocrine gland tumours-new molecular targets in diagnostics and therapy. Eur J Endocrinol 2002; 146(2): 143-51.
23. Ten Bokum AMC, Hofland LJ, van Hagen. Somatostatin and somatostatin receptors in the immune system: a review. Eur Cytokine Net 2000; 11:161-7.
24. Chrubasik J, Meynaider J, Blond S, et al. Somatostatin, a potent analgesic. Lancet 1984; 2(8413): 1208-9.
25. Randic M, Miletic V. Depressant actions of methionineenkephalin and somatostatin in cat dorsal horn neurons activated by noxious stimuli. Brain Res 1978; 152: 196-202.
26. Paice JA, Kroin JS, Penn RD. Analgesic effect of octreotide: therapeutic potential. In: Scarpignato C Ed, Octreotide: from basic science to clinical medicine. Basel, Karger 1996: 270-28.
27. Schusdziarra V, Zyznar E, Rouiller D, et al. Splanchnic somatostatin: a hormonal regulator of nutrient homeostasis. Science 1980; 207(4430): 530-2.
28. Uvnas-Wallensten K. Luminal secretion of gut peptides. Clin Gastroenterol. 1980; 9(3): 545-5.
29. Brazeau P. Somatostatin: a peptide with unexpected physiologic activities. Am J Med 1986; 81(6B): 8-13.
30. Sun QQ, Huguenard JR, Prince DA. Somatostatin inhibits thalamic network oscillations in vitro: actions on the GABAergic neurons of the reticular nucleus. J Neurosci 2002; 22(13): 5374-86.
31. Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci U S A 1992; 89: 251-5.
32. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999; 20(3): 157-198.
33. Sellers LA, Alderton F, Carruthers AM, Schindler M, Humphrey PP. Receptor isoforms mediate opposing proliferative effects through Gtt-activated p38 or Akt pathways. Mol Cell Biol 2000; 20(16): 5974-85.
34. Lewin MJM, Le Romancer M. Somatostatin receptors. In: Scarpignato C Ed, Octreotide: from basic science to clinical medicine. Basel, Karger 1996: 23-34.
35. Reubi JC. Octreotide and nonendocrine tumors: basic knowledge and therapeutic potential. In: Scarpignato C Ed, Octreotide: from basic science to clinical medicine. Basel, Karger 1996: 246-269.
36. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2003; 2(12): 999-1017.
37. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003; 24(1): 28-47.
38. De Jong M, Bernard BF, De Bruin E, et al. Internalization of radiolabelled [DTPA0]octreotide and [DOTA0, Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun 1998; 19(3): 283-8.
39. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000; 288(5463): 154-7.
40. Peters GE. Distribution and metabolism of exogenous somatostatin in the rat. Regul Pept 1982; 3(5-6): 361-9.
41. Patel YC, Wheatley T. In vivo and in vitro plasma disappearance and metabolism of somatostatin-28 and somatostatin-14 in the rat. Endocrinology 1983; 112(1): 220-5.
42. Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31(11): 1133-40.
43. Berta, P.O.: MX01008349A (2004).
44. Parmar H, Bogden A, Mollard M, de Rouge B, Phillips RH, Lightman SL. Somatostatin and somatostatin analogues in oncology. Cancer Treat Rev 1989; 16(2): 95-115.
45. Norman P. Vapreotide (Debipharm). IDrugs 2000; 3(11): 1358-72.
46. Pawlikowski M, Melen-Mucha G. Perspectives of new potential therapeutic applications of somatostatin analogs. Neuro Endocrinol Lett 2003; 24(1-2): 21-7.
47. Pawlikowski M, Melen-Mucha G. Somatostatin analogs-from new molecules to new applications. Curr Opin Pharmacol 2004; 4(6): 608-13.
48. Melmed S. Somatostatin analogs: the breadth of applications and a look into the future. In: Lamberts SWJ Ed, Octreotide: the next decade Bristol, BioScientifica Ltd 1999; 9-25.
49. Panagou E, Lao WC, Burroughs AK. Octreotide and somatostatin in the treatment of bleeding oesopgageal varices. In: Scarpignato C Ed, Octreotide: from basic science to clinical medicine. Basel, Karger 1996; 130-138.
50. Farthing MJG. Treatment of refractory diarrhoeas with octreotide. In: Scarpignato C Ed, Octreotide: from basic science to clinical medicine. Basel, Karger 1996: 166-183.
51. Pederzoli P, Falconi M, Bassi C, Briani G, Camboni MG. Octreotide in preventing complications from pancreatic surgery. In: Scarpignato C Ed, Octreotide: from basic science to clinical medicine. Basel, Karger 1996:192-200.
52. Buchler MW, Friess H, Binder M, Berger HG. Role of octreotide in the medical treatment of acute pancreatitis. In: Scarpignato C Ed, Octreotide: from basic science to clinical medicine. Basel, Karger 1996; 184-191.
53. Scarpignato C, Bruley des Varannes S. Medical mamagement of dumping syndrome: the place of octreotide. In: Scarpignato C Ed, Octreotide: from basic science to clinical medicine. Basel, Karger 1996; 151-165.
54. Weckbecker G, Stolz B, Susini Ch, Bruns Ch. Antiproliferative somatostatin analogues with potential in oncology. In: Lamberts SWJ Ed, Octreotide: the next decade Bristol, BioScientifica Ltd 1999; 339-352.
55. Waxman J. Malignant intestinal obstruction. In: Lamberts SWJ Ed, Octreotide: the next decade Bristol, BioScientifica Ltd 1999; 325-328.
56. Orskov H, Flyvbjerg A, Gronbek H, Moller N. Metabolic and functional effects of somatostatin analogues in diabetes mellitus. In: Lamberts SWJ Ed, Octreotide: the next decade Bristol, Bio-Scientifica Ltd 1999; 195-222.
57. Boehm BO, Feldmann B, Lang GK, Lang GE. Treatment of diabetic retinopathy with long acting somatostatin analogues. In: Lamberts SWJ Ed, Octreotide: the next decade Bristol, BioScientifica Ltd 1999; 241-257.
58. Colao A, Listoria S, Pivonello R, Ferone D, Lombardi G, Fenzi G. Somatostatin analogues and ophthalmic Graves' disease. In: Lamberts SWJ Ed, Octreotide: the next decade Bristol, BioScientifica Ltd 1999; 277-290.
59. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002; 146(5): 707-16.
60. Coy, D.H., Taylor, J.E.: GR3036447T3 (2001).
61. Albert, R.: SE8904087A (1991).
62. Schally, A.V., Nagy, A.A., Cai, R.-Z.: US20016184374 (2001).
63. Culler, M.D., Dong Z.X., Kim, S.H., Moreau, J.-P.: US20040209798A1 (2004).
64. Angelberger, P., Smith-Jones, P., Virgolini, I.: CA2284581AA (1998).
65. Bonasera, T., Fridkin, G., Gilon, C.: US20050226813A1 (2005).
66. Albert R, Smith-Jones P, Stolz B, et al. Direct synthesis of [DOTA-DPhe1]-octreotide and [DOTA-DPhe1, Tyr3]-octreotide (SMT487): two conjugates for systemic delivery of radiotherapeutical nuclides to somatostatin receptor positive tumors in man. Bioorg Med Chem Lett 1998; 8(10): 1207-10.
67. Virgolini I, Szilvasi I, Kurtaran A, et al. Indium-111-DOTAlanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. J Nucl Med 1998; 39(11): 1928-36.
68. Reubi JC. Relevance of Somatostatin Receptors and Other Peptide Receptors in Pathology. Endocr Pathol 1997; 8(1): 11-20.
69. Reubi JC, Laissue J, Krenning E, Lamberts SW. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol 1992; 43(1-3): 27-35.
70. Reubi JC, Landolt AM. High density of somatostatin receptors in pituitary tumors from acromegalic patients. J Clin Endocrinol Metab 1984; 59(6): 1148-51.
71. Reubi JC, Hacki WH, Lamberts SW. Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors. J Clin Endocrinol Metab 1987; 65(6): 1127-34.
72. Papotti M, Bongiovanni M, Volante M, et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 2002; 440(5): 461-75.
73. Reubi JC, Waser B, Khosla S, et al. In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 1992; 74(5): 1082-9.
74. Sagman U, Mullen JB, Kovacs K, Kerbel R, Ginsberg R, Reubi JC. Identification of somatostatin receptors in human small cell lung carcinoma. Cancer 1990; 66(10): 2129-33.
75. Reubi JC, Chayvialle JA, Franc B, Cohen R, Calmettes C, Modigliani E. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 1991; 64(4): 567-73.
76. Papotti M, Kumar U, Volante M, Pecchioni C, Patel YC. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin Endocrinol (Oxf) 2001; 54(5): 641-9.
77. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003; 24(4): 389-427.
78. Hofland LJ, van Koetsveld PM, Waaijers M, Zuyderwijk J, Breeman WA, Lamberts SW. Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide. Endocrinology 1995;136(9): 3698-706.
79. Hofland LJ, Lamberts SWJ. Somatostatin receptor internalization: the physiological concept for targeted radiotherapy. In: Lamberts SWJ Ed, Octreotide: The Next Decade. BioScientifica Ltd, 1999; 27-38.
80. Krenning EP, Bakker WH, Breeman WA, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989; 1(8632): 242-4.
81. van der Lely AJ, de Herder WW, Krenning EP, Kwekkeboom DJ. Octreoscan radioreceptor imaging. Endocrine 2003; 20(3): 307-11.
82. Froidevaux S, Eberle AN. Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers 2002; 66(3): 161-83.
83. Krenning EP, Bakker WH, Kooij PP, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 1992; 33(5): 652-8.
84. Weiner RE, Thakur ML. Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Appl Radiat Isot 2002; 57(5): 749-63.
85. Capello A, Krenning EP, Breeman WA, Bernard BF, Konijnenberg MW, de Jong M. Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitro. Cancer Biother Radiopharm 2003; 18(5): 761-8.
86. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000; 41(10): 1704-13.
87. Froidevaux S, Heppeler A, Eberle AN, et al. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy. Endocrinology 2000; 141(9): 3304-12.
88. Smith-Jones PM, Bischof C, Leimer M, et al. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology 1999; 140(11): 5136-48.
89. Heppeler A, Froidevaux S, Eberle AN, Maecke HR. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 2000; 7(9): 971-94.
90. Froidevaux S, Eberle AN, Christe M, et al. Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model. Int J Cancer 2002; 98(6): 930-7.
91. Virgolini I, Traub T, Novotny C, et al. Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr Pharm Des 2002; 8(20): 1781-807.
92. Wild D, Schmitt JS, Ginj M, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003; 30(10): 1338-47.
93. Wester HJ, Schottelius M, Scheidhauer K, Reubi JC, Wolf I, Schwaiger M. Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics. Eur J Nucl Med Mol Imaging 2002; 29(1): 28-38.
94. Dean, R.T., Lister-James, J.: US19985833942 (1998).
95. Virgolini I, Leimer M, Handmaker H, et al. Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829. Cancer Res 1998; 58(9): 1850-9.
96. Vallabhajosula S, Moyer BR, Lister-James J, et al. Preclinical evaluation of technetium-99m-labeled somatostatin receptorbinding peptides. J Nucl Med 1996; 37(6): 1016-22.
97. Blum JE, Handmaker H, Rinne NA. The utility of a somatostatintype receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules. Chest 1999; 115(1): 224-32.
98. Lebtahi R, Le Cloirec J, Houzard C, et al. Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111Inpentetreotide scintigraphy. J Nucl Med 2002; 43(7): 889-95.
99. Bangard M, Behe M, Guhlke S, et al. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNICD-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide. Eur J Nucl Med 2000; 27(6): 628-37.
100. de Jong M, Breeman WA, Bakker WH, et al. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 1998; 58(3): 437-41.
101. Lewis JS, Srinivasan A, Schmidt MA, Anderson CJ. In vitro and in vivo evaluation of 64Cu-TETA-Tyr3-octreotate. A new somatostatin analog with improved target tissue uptake. Nucl Med Biol 1999; 26(3): 267-73.
102. Reubi JC, Schar JC, Waser B, et al. ffinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000; 27(3): 273-82.
103. Wester HJ, Brockmann J, Rosch F, et al. PET-pharmacokinetics of 18F-octreotide: a comparison with 67Ga-DFO-and 86YDTPA-octreotide. Nucl Med Biol 1997; 24(4): 275-86.
104. Smith-Jones PM, Stolz B, Bruns C, et al. Gallium-67/gallium-68-[DFO]-octreotide-a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. J Nucl Med 1994; 35(2): 317-25.
105. Anderson CJ, Dehdashti F, Cutler PD, et al. 64Cu-TETAoctreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 2001; 42(2): 213-21.
106. Hofmann M, Maecke H, Borner R, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001; 28(12): 1751-7.
107. Reubi JC. Somatostatin and other Peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology. 2004; 80 Suppl 1: 51-6.
108. Reubi JC, Waser B, Liu Q, Laissue JA, Schonbrunn A. Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location. Clin Endocrinol Metab 2000; 85(10): 3882-91.
109. Papotti M, Croce S, Bello M, et al. Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy. Virchows Arch 2001; 439(6): 787-97.
110. Janson ET, Stridsberg M, Gobl A, Westlin JE, Oberg K. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies. Cancer Res 1998; 58(11): 2375-8.
111. Duet M, Ajzenberg C, Benelhadj S, et al. Somatostatin receptor scintigraphy in pituitary adenomas: a somatostatin receptor density index can predict hormonal and tumoral efficacy of octreotide in vivo. J Nucl Med 1999; 40(8): 1252-6.
112. Legovini P, De Menis E, Billeci D, Conti B, Zoli P, Conte N. 111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients. J Endocrinol Invest 1997; 20(7): 424-8.
113. Broson-Chazot F, Houzard C, Ajzenberg C, et al. omatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide. Clin Endocrinol (Oxf) 1997; 47(5): 589-98.
114. de Herder WW, Hofland LJ, van der Lely AJ, Lamberts SW. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer 2003; 10(4): 451-8.
115. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004; 25(3): 458-511.
116. Kaltsas G, Rockall A, Papadogias D, Reznek R, Grossman AB. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol 2004;151(1): 15-27.
117. Forssell-Aronsson E, Bernhardt P, Nilsson O, Tisell LE, Wangberg B, Ahlman H. Biodistribution data from 100 patients i.v. injected with 111In-DTPA-D-Phe1-octreotide. Acta Oncol 2004; 43(5): 436-42.
118. Westlin JE, Janson ET, Arnberg H, Ahlstrom H, Oberg K, Nilsson S. Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide. Acta Oncol 1993; 32(7-8): 783-6.
119. Gibril F, Reynolds JC, Lubensky IA, et al. Ability of somatostatin receptor scintigraphy to identify patients with gastric carcinoids: a prospective study. J Nucl Med 2000; 41(10): 1646-56.
120. Traub T, Petkov V, Ofluoglu S, et al. 111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung. J Nucl Med 2001; 42(9): 1309-15.
121. Kaltsas G, Korbonits M, Heintz E, et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 2001; 86(2): 895-902.
122. Isidori AM, Kaltsas G, Frajese V, et al. Ocular metastases secondary to carcinoid tumors: the utility of imaging with [(123)I]metaiodobenzylguanidine and [(111)In]DTPA pentetreotide. J Clin Endocrinol Metab 2002; 87(4): 1627-33.
123. Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 1996; 125(1): 26-34.
124. Termanini B, Gibril F, Reynolds JC, et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997; 112(2): 335-47.
125. Alexander HR, Fraker DL, Norton JA, et al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg 1998; 228(2): 228-38.
126. van Eijck CH, Lamberts SW, Lemaire LC, et al. he use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors. Ann Surg 1996; 224(2): 119-24.
127. Gibril F, Doppman JL, Reynolds JC, et al. Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect of their detection on management. J Clin Oncol 1998; 16(3): 1040-53.
128. Sall JW, O'Dorisio MS, O'Dorisio TM. Biology of neuroendocrine tumors. In: Lamberts SWJ Ed, Octreotide: The Next Decade. BioScientifica Ltd, 1999; 117-131.
129. van der Harst E, de Herder WW, Bruining HA, et al. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001; 86(2): 685-93.
130. Mundschenk J, Unger N, Schulz S, et al. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab 2003; 88(11): 5150-7.
131. Kopf D, Bockisch A, Steinert H, et al. Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma. Clin Endocrinol (Oxf) 1997; 46(1): 39-44.
132. Kaltsas GA, Mukherjee JJ, Grossman AB. The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours. Ann Oncol 2001; 12 Suppl 2: S47-50.
133. Tisell LE, Ahlman H, Wangberg B, et al. Somatostatin receptor scintigraphy in medullary thyroid carcinoma. Br J Surg 1997; 84(4): 543-7.
134. Kwekkeboom DJ, Reubi JC, Lamberts SW, et al. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 1993; 76(6): 1413-7.
135. Kwekkeboom DJ, Kho GS, Lamberts SW, Reubi JC, Laissue JA, Krenning EP. The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med 1994; 21(10): 1106-13.
136. Reisinger I, Bohuslavitzki KH, Brenner W, et al. Somatostatin receptor scintigraphy in small-cell lung cancer: results of a multicenter study. J Nucl Med 1998; 39(2): 224-7.
137. Gotthardt M, Behe MP, Alfke H, Behr TM. Imaging lung tumors with peptide-based radioligands. Clin Lung Cancer 2003; 5(2): 119-24.
138. de Herder WW, Krenning EP, Malchoff CD, et al. Somatostatin receptor scintigraphy: its value in tumor localization in patients with Cushing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion. Am J Med 1994; 96(4): 305-12.
139. Tsagarakis S, Christoforaki M, Giannopoulou H, et al. A reappraisal of the utility of somatostatin receptor scintigraphy in patients with ectopic adrenocorticotropin Cushing's syndrome. J Clin Endocrinol Metab 2003; 88(10): 4754-8.
140. Pena Gonzalez E, Lampreave Marquez JL, Leon Atance P, Moreno Esteban B, Bittini Copano A, Folque Gomez E. Cushing's syndrome secondary to bronchial carcinoid tumor: contribution of gammagraphy with 111In-DTPA octreotide in the localization diagnosis. An Med Interna 1999; 16(11): 577-9.
141. Fernandez-Fernandez F, Halperin I, Manzanares JM, Flores L, Lomena F, Vilardell E. Localization and postoperative follow-up of a bronchial carcinoid tumor causing Cushing's syndrome by 111In-DTPA labelled octreotide scintigraphy. J Endocrinol Invest 1997; 20(6): 327-30.
142. Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumours. Endocr Relat Cancer 2004; 11(1): 1-18.
143. Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15(6): 966-73.
144. Plockinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004; 80(6): 394-424.
145. Guida T, Belsito Petrizzi V, Fiorentino R, et al. State of the art and therapeutic prospects in neuroectodermal tumours and other neuroendocrine pathologies. Minerva Endocrinol 2001; 26(4): 215-24.
146. Ezzat S, Ren SG, Braunstein GD, Melmed S. Octreotide stimulates insulin-like growth factor-binding protein-1: a potential pituitary-independent mechanism for drug action. J Clin Endocrinol Metab 1992; 75(6): 1459-63.
147. Lawnicka H, Stepien H, Wyczolkowska J, Kolago B, Kunert-Radek J, Komorowski J. Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture. Biochem Biophys Res Commun 2000; 268(2): 567-71.
148. Li M, Zhang R, Li F, et al. Transfection of SSTR-1 and SSTR-2 inhibits Panc-1 cell proliferation and renders Panc-1 cells responsive to somatostatin analogue. J Am Coll Surg 2005; 201(4): 571-8.
149. Wasko R, Jankowska A, Kotwicka M, Liebert W, Sowinski J, Warchol JB. Effects of treatment with somatostatin analogues on the occurrence of apoptosis in somatotropinomas. Neuro Endocrinol Lett 2003; 24(5): 334-8.
150. Teunissen JJ, Kwekkeboom DJ, de Jong M, Esser JP, Valkema R, Krenning EP. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol 2005; 19(4): 595-616.
151. Grass P, Marbach P, Bruns C, Lancranjan I. Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships. Metabolism 1996; 45(8 Suppl 1): 27-30.
152. Bevan JS. Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005; 90(3): 1856-63.
153. Ayuk J, Stewart SE, Stewart PM, Sheppard MC; European Sandostatin LAR Group. Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clin Endocrinol (Oxf) 2004; 60(3): 375-81.
154. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005; 90(8): 4465-73.
155. van der Hoek J, van der Lelij AJ, Feelders RA, et al. The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. Clin Endocrinol (Oxf) 2005; 63(2): 176-84.
156. Jaquet P, Ouafik L, Saveanu A, et al. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J Clin Endocrinol Metab 1999; 84(9): 3268-76.
157. Ferone D, Pivonello R, Lastoria S, et al. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy. Clin Endocrinol (Oxf) 2001; 54(4): 469-77.
158. Jaquet P, Gunz G, Saveanu A, et al. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GHsecreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol 2005; 153(1): 135-41.
159. Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas. Clin Endocrinol (Oxf) 1994; 40(3): 421-8.
160. Fischler MP, Reinhart WH. TSH-secreting pituitary macroadenoma: rapid tumor shrinkage and recovery from hyperthyroidism with octreotide. J Endocrinol Invest 1999; 22(1): 64-5.
161. Andersen M, Bjerre P, Schroder HD, et al. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas. Clin Endocrinol (Oxf) 2001; 54(1): 23-30.
162. Lamberts SW, Uitterlinden P, Klijn JM. The effect of the longacting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease. Acta Endocrinol (Copenh) 1989; 120(6): 760-6.
163. Kelestimur F, Utas C, Ozbakir O, Selcuklu A, Kandemir O, Ozcan N. The effects of octreotide in a patient with Nelson's syndrome. Postgrad Med J 1996; 72(843): 53-4.
164. van der Hoek J, Lamberts SW, Hofland LJ. The Role of Somatostatin Analogs in Cushing's Disease. Pituitary 2004; 7(4): 257-64.
165. Ramage JK, Davies AH, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005; 54 Suppl 4: iv1-16.
166. Wynick D, Bloom SR. Clinical review 23: The use of the longacting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors. J Clin Endocrinol Metab 1991; 73(1): 1-3.
167. Comaru-Schally AM, Schally AV. A clinical overview of carcinoid tumors: perspectives for improvement in treatment using peptide analogs (review). Int J Oncol 2005; 26(2): 301-9.
168. O'Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: A perspective crossover evaluation of lanreotide versus octreotidein terms of efficacy, potent acceptability and tolerance. Cancer 2000; 88; 770-776.
169. Shojamanesh H, Gibril F, Louie A, et al. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 2002; 94(2): 331-43.
170. Saijo F, Naito H, Funayama Y, et al. Octreotide in control of multiple liver metastases from gastrinoma. J Gastroenterol 2003; 38(9): 905-8.
171. Buscombe JR, Caplin ME, Hilson AJ. Long-term efficacy of highactivity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med 2003; 44: 1-6.
172. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In-and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002; 32(2): 148-55.
173. Grossrubatscher E, Vignati F, Dalino P, et al. Use of radioguided surgery with [111In]-pentetreotide in the management of an ACTH-secreting bronchial carcinoid causing ectopic Cushing's syndrome. J Endocrinol Invest 2005; 28(1): 72-8.
174. Ilias I, Torpy DJ, Pacak K, Mullen N, Wesley RA, Nieman LK. Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab 2005; 90(8): 4955-62.
175. Sonino N, Boscaro M, Fallo F. Pharmacologic management of Cushing syndrome: new targets for therapy. Treat Endocrinol 2005; 4(2): 87-94.
176. Lefebvre S, De Paepe L, Abs R, Rahier J, Selvais P, Maiter D. Subcutaneous octreotide treatment of a growth hormone-releasing hormone-secreting bronchial carcinoid: superiority of continuous versus intermittent administration to control hormonal secretion. Eur J Endocrinol 1995; 133(3): 320-4.
177. Vainas I, Koussis Ch, Pazaitou-Panayiotou K, et al. Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma. J Exp Clin Cancer Res 2004; 23(4): 549-59.
178. Bodei L, Handkiewicz-Junak D, Grana C, et al. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother Radiopharm 2004; 19(1): 65-71.
179. Unger N, Serdiuk I, Sheu SY, et al. Immunohistochemical determination of somatostatin receptor subtypes 1, 2A, 3, 4, and 5 in various adrenal tumors. Endocr Res 2004; 30(4): 931-4.
180. Lamarre-Cliche M, Gimenez-Roqueplo AP, Billaud E, Baudin E, Luton JP, Plouin PF. Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma. Clin Endocrinol (Oxf) 2002; 57(5): 629-34.
181. Bustillo A, Telischi FF. Octreotide scintigraphy in the detection of recurrent paragangliomas. Otolaryngol Head Neck Surg 2004; 130(4): 479-82.
182. Tonyukuk V, Emral R, Temizkan S, Sertcelik A, Erden I, Corapcioglu D. Case report: patient with multiple paragangliomas treated with long acting somatostatin analogue. Endocr J 2003; 50(5): 507-13.
183. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001; 12: 941-945.
184. Valkema R, De Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 2002; 32: 110-122.
185. Schmitt M. Merkel cell tumor of the skin. Dtsch Med Wochenschr 1997; 122(45): 1403.
186. Durani BK, Klein A, Henze M, Haberkorn U, Hartschuh W. Somatostatin analogue scintigraphy in Merkel cell tumours. Br J Dermatol 2003; 148(6): 1135-40.
187. Meier G, Waldherr C, Herrmann R, Maecke H, Mueller-Brand J, Pless M. Successful targeted radiotherapy with 90Y-DOTATOC in a patient with Merkel cell carcinoma. A Case Report. Oncology 2004; 66(2): 160-3.
188. Michael, D.C., Yeelana, S., Zheng, X.D.: AU4229437AA (2004).
189. Bonasera, T.A., Livnah, N., Salitra, Y., Yechezkei, T.: US20050090429A1 (2005).
190. Bonasera, T., Fridkin, G., Gilon, C.: US20050226813A1 (2005).